Welcome to our dedicated page for First Tracks Biotherapeutics SEC filings (Ticker: TRAXV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on First Tracks Biotherapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into First Tracks Biotherapeutics's regulatory disclosures and financial reporting.
First Tracks Biotherapeutics director Ware J. Anthony reported equity awards and holdings following the company’s spin-off from AnaptysBio. He holds 9,630 shares of common stock received in the pro rata distribution tied to the Separation and Distribution Agreement dated April 20, 2026.
He also acquired multiple stock options and restricted stock units that were adjusted from prior AnaptysBio awards. These include RSUs for 4,000 and 6,030 shares of common stock, each RSU representing one share upon settlement at no cost, plus several fully vested and time‑vested stock options with exercise prices between $3.97 and $28.03 per share and expirations between 2027 and 2036. The RSUs are scheduled to vest in full at the company’s 2026 and 2027 annual shareholder meetings, subject to continued service.
Schmid John P. reported acquisition or exercise transactions in this Form 4 filing.
First Tracks Biotherapeutics director John P. Schmid reported equity awards and spin-off related holdings. He directly holds 31,622 shares of common stock received in connection with the spin-off from AnaptysBio. Schmid also holds restricted stock units and multiple stock option grants that provide additional exposure to First Tracks shares.
He was granted 4,000 RSUs vesting in full on the company’s 2026 annual shareholder meeting and 6,030 RSUs vesting in full at the 2027 meeting, each settling into one share of common stock per unit for no cash cost. Footnotes state that his stock options and RSUs were adjusted under a Separation and Distribution Agreement so that awards now cover both First Tracks and AnaptysBio. One option grant is fully vested, while another vests in 12 equal monthly installments beginning February 6, 2026.
Orwin John A reported acquisition or exercise transactions in this Form 4 filing.
First Tracks Biotherapeutics director John A. Orwin reported new equity awards tied to the spin-off from AnaptysBio. He holds 10,665 shares of common stock received in a pro rata distribution at separation.
On April 20, 2026, he was credited with three restricted stock unit blocks of 6,000, 6,030 and 1,300 RSUs, each representing one common share upon settlement for no cash consideration. These RSUs include tranches vesting in thirds on September 15, 2024, 2025 and 2026, plus separate grants vesting 100% on the company’s 2026 and 2027 annual shareholder meeting dates, subject to continued service.
He also received or had adjusted stock options over common shares, including 8,250 options at $11.75 per share that are fully vested, and additional options for 16,510 shares at $3.97, 16,510 at $5.67, and 10,600 and 3,311 at $5.22 per share, with expirations between 2033 and 2036 and vesting schedules commencing monthly from February 6, 2026. Footnotes state these option and RSU positions were adjusted so that AnaptysBio awards became awards in both AnaptysBio and First Tracks under their Separation and Distribution Agreement.
First Tracks Biotherapeutics director Dennis M. Fenton reported new equity awards tied to the spin-off from AnaptysBio and his board service. He now directly holds 4,965 shares of common stock received in the pro rata distribution from AnaptysBio.
On April 20, 2026, he acquired 4,000 and 6,030 Restricted Stock Units, each RSU representing one share of common stock upon settlement for no consideration. He also received multiple stock options to buy First Tracks common stock at exercise prices ranging from $3.97 to $31.82 per share with expirations between 2028 and 2036. Some options are fully vested, while others vest monthly starting February 6, 2026, and certain RSUs vest 100% on the company’s 2026 and 2027 annual meeting dates.
First Tracks Biotherapeutics, Inc. director Rita Jain reported equity awards and holdings in connection with the company’s separation from AnaptysBio. She directly holds 11,864 shares of common stock, including shares received in the spin-off distribution from AnaptysBio.
On April 20, 2026, Jain was credited with multiple stock options and restricted stock units (RSUs) that reflect adjustments under the Separation and Distribution Agreement. The filing lists stock options covering 5,500, 16,510, 16,510, 8,015, and 10,600 shares of common stock at exercise prices ranging from $3.97 to $11.75 per share, with expirations between 2033 and 2036. One option is fully vested, while another vests in twelfths monthly starting on February 6, 2026.
The RSU awards cover 4,000, 6,030, and 1,300 units, each representing the right to receive one share of common stock for no consideration. RSUs vest in tranches on June 15, 2024, June 15, 2025, and June 15, 2026, and in full on the dates of the issuer’s 2026 and 2027 annual meetings of shareholders, in each case subject to continued service.
First Tracks Biotherapeutics, Inc. reported an insider transaction by AnaptysBio, Inc., a ten percent owner, related to a corporate restructuring. AnaptysBio previously held 100 shares of First Tracks common stock, which represented all issued and outstanding shares.
On the April 20, 2026 record date, AnaptysBio distributed these 100 shares to its own stockholders in a Spin-Off that occurred before the market opened that day. Following this distribution, AnaptysBio reported holding 0 shares of First Tracks common stock, indicating its ownership position in First Tracks was fully distributed.
First Tracks Biotherapeutics, Inc. President and CEO Daniel Faga reported equity awards and holdings rather than open-market trades. He directly holds 496,684 shares of common stock and received multiple grants of restricted stock units, each RSU representing a right to one common share.
The filing also shows several employee stock options to acquire common stock at exercise prices ranging from $3.97 to $11.75 per share with expirations between 2031 and 2036. Footnotes explain these options and RSUs were adjusted and granted in connection with AnaptysBio’s spin-off of First Tracks under a Separation and Distribution Agreement.
First Tracks Biotherapeutics director Magda Marquet reported new equity awards and spin-off related holdings. She holds 9,930 shares of common stock received in the pro rata distribution from AnaptysBio under the Separation and Distribution Agreement. On the derivative side, she was granted 4,000 restricted stock units that vest in full on the company’s 2026 annual meeting date and 6,030 RSUs that vest in full on the 2027 annual meeting date, each RSU convertible into one common share for no cash payment. She also holds multiple stock options to buy First Tracks common stock, including 5,500 options at an exercise price of $11.75 per share that are fully vested and 16,510 options at $3.97 per share that vest monthly over 12 months starting February 6, 2026, along with several older option grants at exercise prices between $6.22 and $8.14 per share.
First Tracks Biotherapeutics, Inc. became an independent, publicly traded biotech company through a spin-off from AnaptysBio, with AnaptysBio shareholders receiving one First Tracks share for each AnaptysBio share held on the April 6, 2026 record date. The company simultaneously closed a private placement in which it issued 5,791,478 shares of common stock and EcoR1 Capital Fund Qualified, L.P. sold 4,705,575 of its spin-off shares to investors at $13.81 per share. A Separation and Distribution Agreement and a Transition Services Agreement allocate assets, liabilities, services and IP between AnaptysBio and First Tracks and govern post-spin relations. The company also adopted non-employee director cash and equity compensation programs and appointed Ajim Tamboli as Chief Financial Officer with a $516,000 base salary, target bonus opportunity and equity awards valued at $2,550,000. First Tracks’ lead programs include ANB033 for celiac disease and eosinophilic esophagitis, rosnilimab for rheumatoid arthritis and ANB101 in early-stage development, and its stock began trading on Nasdaq under the symbol TRAX.
First Tracks Biotherapeutics, Inc. outlines its planned separation from AnaptysBio through a taxable spin-off and concurrent private financing. AnaptysBio stockholders of record on April 6, 2026 will receive one First Tracks share for each AnaptysBio share when the distribution occurs on April 20, 2026.
First Tracks shares are expected to trade on Nasdaq under the symbol “TRAX”, with when-issued trading under “TRAXV” beginning April 6, 2026. A private placement will sell 5,791,478 new shares at $13.81 per share, targeting about $80 million in gross proceeds to fund the company’s clinical-stage immunology pipeline.